Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy
- PMID: 33918041
- PMCID: PMC8068954
- DOI: 10.3390/ijms22083869
Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy
Abstract
Cerebral amyloid angiopathy (CAA) is characterized by accumulation of amyloid β (Aβ) in walls of leptomeningeal vessels and cortical capillaries in the brain. The loss of integrity of these vessels caused by cerebrovascular Aβ deposits results in fragile vessels and lobar intracerebral hemorrhages. CAA also manifests with progressive cognitive impairment or transient focal neurological symptoms. Although development of therapeutics for CAA is urgently needed, the pathogenesis of CAA remains to be fully elucidated. In this review, we summarize the epidemiology, pathology, clinical and radiological features, and perspectives for future research directions in CAA therapeutics. Recent advances in mass spectrometric methodology combined with vascular isolation techniques have aided understanding of the cerebrovascular proteome. In this paper, we describe several potential key CAA-associated molecules that have been identified by proteomic analyses (apolipoprotein E, clusterin, SRPX1 (sushi repeat-containing protein X-linked 1), TIMP3 (tissue inhibitor of metalloproteinases 3), and HTRA1 (HtrA serine peptidase 1)), and their pivotal roles in Aβ cytotoxicity, Aβ fibril formation, and vessel wall remodeling. Understanding the interactions between cerebrovascular Aβ deposits and molecules that accumulate with Aβ may lead to discovery of effective CAA therapeutics and to the identification of biomarkers for early diagnosis.
Keywords: amyloid β; cerebral amyloid angiopathy; cerebral microbleeds; intracerebral hemorrhage; proteomic analyses; superficial siderosis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

References
-
- Xuereb J.H., Brayne C., Dufouil C., Gertz H., Wischik C., Harrington C., Mukaetova-Ladinska E., McGee M.A., O’Sullivan A., O’Connor D., et al. Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann. N. Y. Acad. Sci. 2000;903:490–496. doi: 10.1111/j.1749-6632.2000.tb06404.x. - DOI - PubMed
-
- Neuropathology Group: Medical Research Council Cognitive Function and Aging Study Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) Lancet. 2001;357:169–175. doi: 10.1016/S0140-6736(00)03589-3. - DOI - PubMed
-
- Tanskanen M., Lindsberg P.J., Tienari P.J., Polvikoski T., Sulkava R., Verkkoniemi A., Rastas S., Paetau A., Kiuru-Enari S. Cerebral amyloid angiopathy in a 95+ cohort: Complement activation and apolipoprotein E (ApoE) genotype. Neuropathol. Appl. Neurobiol. 2005;31:589–599. doi: 10.1111/j.1365-2990.2005.00652.x. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 19K16919/Grants-in-Aid for Young Scientists from the Japan Society for the Promotion of Science (JSPS)
- 19KK0410/Promotion of Joint International Research (Fostering Joint International Research (A)) from the JSPS
- none/The Japan Foundation of Applied Enzymology
- none/Kanae Foundation for Life & Socio-Medical Science
- none/The Uehara Memorial Foundation
LinkOut - more resources
Full Text Sources
Other Literature Sources